{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:33:14Z","timestamp":1772137994783,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001422"],"award-info":[{"award-number":["UL1TR001422"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Key points<\/jats:title>\n                    <jats:p>In a multicenter point-prevalence study, we found that the rate of supportive care was high; among those receiving COVID-19 drug therapies, adverse reactions occurred in 12% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>There are currently no FDA-approved medications for the treatment of coronavirus disease 2019 (COVID-19). At the onset of the pandemic, off-label medication use was supported by limited or no clinical data. We sought to characterize experimental COVID-19 therapies and identify safety signals during this period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a noninterventional, multicenter, point prevalence study of patients hospitalized with suspected\/confirmed COVID-19. Clinical and treatment characteristics within a 24-hour window were evaluated in a random sample of up to 30 patients per site. The primary objective was to describe COVID-19\u2013targeted therapies. The secondary objective was to describe adverse drug reactions (ADRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 352 patients treated for COVID-19 at 15 US hospitals From April 18 to May 8, 2020, were included in the study. Most patients were treated at academic medical centers (53.4%) or community hospitals (42.6%). Sixty-seven patients (19%) were receiving drug therapy in addition to supportive care. Drug therapies used included hydroxychloroquine (69%), remdesivir (10%), and interleukin-6 antagonists (9%). Five patients (7.5%) were receiving combination therapy. The rate of use of COVID-19\u2013directed drug therapy was higher in patients with vs patients without a history of asthma (14.9% vs 7%, P = 0.037) and in patients enrolled in clinical trials (26.9% vs 3.2%, P &amp;lt; 0.001). Among those receiving drug therapy, 8 patients (12%) experienced an ADR, and ADRs were recognized at a higher rate in patients enrolled in clinical trials (62.5% vs 22%; odds ratio, 5.9; P = 0.028).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While we observed high rates of supportive care for patients with COVID-19, we also found that ADRs were common among patients receiving drug therapy, including those enrolled in clinical trials. Comprehensive systems are needed to identify and mitigate ADRs associated with experimental COVID-19 treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaa426","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T19:38:30Z","timestamp":1612553910000},"page":"568-577","source":"Crossref","is-referenced-by-count":4,"title":["Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States"],"prefix":"10.1093","volume":"78","author":[{"given":"Nathaniel J","family":"Rhodes","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA"},{"name":"Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, IL, USA"},{"name":"Pharmacometrics Center of Excellence, Midwestern University Chicago College of Pharmacy, Downers Grove, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atheer","family":"Dairem","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anooj","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA"},{"name":"Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Postelnick","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa E","family":"Badowski","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah M","family":"Michienzi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime L","family":"Borkowski","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Northwestern Medicine Delnor Hospital, Geneva, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika S","family":"Polisetty","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, IL, USA"},{"name":"Department of Pharmacy, Northwestern Medicine Central DuPage Hospital, Winfield, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Fong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Utah Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily S","family":"Spivak","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Utah School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R","family":"Beardsley","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wake Forest Baptist Health, Winston-Salem, NC, USA"},{"name":"Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cory M","family":"Hale","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea M","family":"Pallotta","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cleveland Clinic Hospital, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavithra","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cleveland Clinic Hospital, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas T","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Health, Madison WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"2021031809433393400_CIT0001","author":"Centers for Disease Control and Prevention"},{"issue":"4","key":"2021031809433393400_CIT0002","doi-asserted-by":"crossref","first-page":"ofaa105","DOI":"10.1093\/ofid\/ofaa105","article-title":"Coronavirus disease 2019 treatment: a review of early and emerging options","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect Dis."},{"key":"2021031809433393400_CIT0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.2402","article-title":"Need for transparency and reliable evidence in emergency use authorizations for coronavirus disease 2019 (COVID-19) therapies","author":"Zhai","year":"2020","journal-title":"JAMA Intern Med."},{"key":"2021031809433393400_CIT0004","author":"COVID-19 Treatment Guidelines Panel, National Institutes of Health"},{"key":"2021031809433393400_CIT0005","year":"2020"},{"key":"2021031809433393400_CIT0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106009","article-title":"Tocilizumab in COVID-19: beware the risk of intestinal perforation","author":"Vikse","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"2021031809433393400_CIT0007","author":"Food and Drug Administration"},{"issue":"1","key":"2021031809433393400_CIT0008","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1469-0691.2005.01273.x","article-title":"Prevalence surveys of healthcare-associated infections: what do they tell us, if anything?","volume":"12","author":"Humphreys","year":"2006","journal-title":"Clin Microbiol Infect."},{"issue":"1","key":"2021031809433393400_CIT0009","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/sj.ebd.6400375","article-title":"Study design III: cross-sectional studies","volume":"7","author":"Levin","year":"2006","journal-title":"Evid Based Dent."},{"key":"2021031809433393400_CIT0010","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform."},{"issue":"2","key":"2021031809433393400_CIT0011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCAP)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform."},{"key":"2021031809433393400_CIT0012","author":"Centers for Disease Control and Prevention"},{"issue":"19","key":"2021031809433393400_CIT0013","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19 \u2014 preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med."},{"key":"2021031809433393400_CIT0014","author":"US Food and Drug Administration"},{"key":"2021031809433393400_CIT0015","author":"US National Institutes of Health","year":"2020"},{"key":"2021031809433393400_CIT0016","author":"US Food and Drug Administration","year":"2020"},{"key":"2021031809433393400_CIT0017","volume-title":"Requirements for Adverse Drug Reaction Reporting","author":"World Health Organization","year":"1975"},{"issue":"1","key":"2021031809433393400_CIT0018","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","journal-title":"Kidney Int Suppl."},{"issue":"10","key":"2021031809433393400_CIT0019","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med."},{"issue":"20","key":"2021031809433393400_CIT0020","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA."},{"issue":"16","key":"2021031809433393400_CIT0021","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jama.2020.4326","article-title":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State","volume":"323","author":"Arentz","year":"2020","journal-title":"JAMA."},{"issue":"8","key":"2021031809433393400_CIT0022","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jamainternmed.2020.2233","article-title":"Outbreak investigation of COVID-19 among residents and staff of an independent and assisted living community for older adults in Seattle, Washington","volume":"180","author":"Roxby","year":"2020","journal-title":"JAMA Intern Med."},{"issue":"19","key":"2021031809433393400_CIT0023","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1001\/jama.2020.4984","article-title":"Optimizing the trade-off between learning and doing in a pandemic","volume":"323","author":"Angus","year":"2020","journal-title":"JAMA."},{"issue":"19","key":"2021031809433393400_CIT0024","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/jama.2020.4742","article-title":"Treating COVID-19 \u2013 off-label drug use, compassionate use, and randomized clinical trials during pandemics","volume":"323","author":"Kalil","year":"2020","journal-title":"JAMA."},{"issue":"19","key":"2021031809433393400_CIT0025","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med."},{"key":"2021031809433393400_CIT0026","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with COVID-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl J Med."},{"key":"2021031809433393400_CIT0027","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","author":"Mehra","journal-title":"Lancet."},{"key":"2021031809433393400_CIT0028","article-title":"A mysterious company\u2019s coronavirus papers in top medical journals may be unraveling","author":"Servick","year":"2020","journal-title":"Science."},{"key":"2021031809433393400_CIT0029","article-title":"Safety fears over hyped drug hydroxychloroquine spark global confusion","author":"Ledford","year":"2020","journal-title":"Nature."},{"issue":"20","key":"2021031809433393400_CIT0030","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2021031809433393400_CIT0031","author":"Sanofi","year":"2020"},{"key":"2021031809433393400_CIT0032","author":"Roche","year":"2020"},{"key":"2021031809433393400_CIT0033","article-title":"Actemra (tocilizumab).","volume-title":"Micromedex Drugdex [proprietary data]"},{"issue":"10236","key":"2021031809433393400_CIT0034","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet."},{"key":"2021031809433393400_CIT0035","article-title":"Remdesivir for 5 or 10 days in patients with severe COVID-19","author":"Goldman","journal-title":"N Engl J Med."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaa426\/36187184\/zxaa426.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/7\/568\/36635468\/zxaa426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/78\/7\/568\/36635468\/zxaa426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T05:43:58Z","timestamp":1616046238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/78\/7\/568\/6127461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,2,26]]},"published-print":{"date-parts":[[2021,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaa426","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.06.03.20121558","asserted-by":"object"}]},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,2,26]]}}}